打破假设:在复发性复发性多发性硬化症中,疾病修饰疗法的疗效和复发的严重程度
Luis A Rodriguez de Antonio1, Inmaculada García-Castañón1, Inés González-Suárez2
1Department of Neurology, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Multiple sclerosis and related disorders
|October 2, 2025
概括
复发性复发性多发性硬化症 (RRMS) 的疾病修饰性治疗 (DMT) 不能显著改变复发的严重程度或恢复. 该研究发现基线残疾,而不是DMT疗效,是影响复发严重性的主要因素.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 疾病修饰治疗 (DMT) 与不治疗相比,可以减少多发性硬化症 (MS) 复发的严重程度.
- 对于预防复发的DMT疗效存在显著差异,但它们对复发严重性的影响未得到充分研究.
研究的目的:
- 调查DMT使用,复发严重程度和复发性复发性多发性硬化症 (RRMS) 患者的康复结果之间的关系.
主要方法:
- 一项回顾性队列研究包括85名RRMS患者.
- 患者被分为中等效率 (n=48) 或高效率 (n=37) 的DMT组.
- 扩展残疾状态量表 (EDSS) 的评估评估了复发的严重程度和恢复.
主要成果:
- 高效的DMT显示出较轻重复发的趋势 (ΔEDSS = 0.49 ± 0.59) 与中度有效的DMT (ΔEDSS = 0.71 ± 0.68) 相比,但这在统计学上并不显著 (p = 0.12).
- 多变量分析没有证实高效治疗对复发严重性的显著影响 (OR = 0.46;p=0.22).
- 基线EDSS是复发严重程度的主要决定因素 (OR=0.40;p=0.006). 恢复在两组中都显示出类似的逐步改善,没有统计学上显著的差异.
结论:
- 分析的DMT的疗效水平 (中度和高疗效) 并没有显著影响复发的严重程度或复发后的恢复.
- 基线残疾是确定RRMS患者复发严重性的关键因素.
相关概念视频
Therapeutic Drug Monitoring: Affecting Factors
201
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
201
Drug Therapy
245
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
245
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493


